[Pharmacological studies of N-4-(hydroxycarbophenyl) retinamide].
Our studies show that the growth of transplantable chondrosarcoma in rats is inhibited significantly by N-4-(hydroxycarbophenyl) retinamide (RII) at a dosage of 50 mg/kg. RII show a weak ability to induce the differentiation of HL-60 cells at a concentration of 1 umol/L. However, most of the HL-60 cells were induced to differentiate along granulocyte lineage after exposure to RII (1 mumol/L) and S86019 (10 micrograms/ml). Flow cytometry studies indicated that the majority of HL-60 cells were arrested in G1 phase by RII plus S86019. Northern blot analysis clearly demonstrated that c-myc expression was inhibited after treating HL-60 cells with RII plus S86019 for 12 hours. Moreover, thymidylate synthetase mRNA transcription was inhibited in those differentiated cells.
Han
R
R
Institute of Materia Medica, Beijing.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D002813:Chondrosarcoma / Q000188:drug therapy / Q000473:pathology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D016259:Genes, myc; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics / Q000473:pathology; D008297:Male; D051381:Rats; D014212:Tretinoin / Q000031:analogs & derivatives* / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000970:Antineoplastic Agents; D014212:Tretinoin; C045860:N-(4-carboxyphenyl)retinamide